Abstract
Insulin-like growth factors (IGFs) constitute a system of peptides that promote mitosis, growth, and organ development by both paracrine and endocrine pathways, their bioavailability being modulated by at least six specific IGF-binding proteins (IGFBP). In type 1diabetic pregnancies IGF-I and -II in maternal serum are associated with birth weight and their action modulated by IGFBP-3 and phosporylated isoforms of IGFBP-1. Pregnancy-associated plasma protein-A (PAPP-A), a proteolytic substance of IGFBPs, is probably a modulator in early diabetic pregnancy while human placental growth hormone (hPGH) regulates the effect of IGF-I in pregnancy of diabetic and non-diabetic pregnancies. IGF-I in maternal serum increases concomitantly with progression of diabetic retinopathy despite good glycemic control in pregnancy. The role of the new insulin analogues in improving this effect has yet to be established. Retinopathy in pregnancy is associated with an elevated level of fibroblast growth factor-2 (FGF-2) and highly-phosphorylated IGFBP-1, the latter further increasing the level of free IGF-I and FGF-2. Thus, the effect on development of retinopathy may be directly mediated by IGF-I or indirectly by a modifying effect of IGFBP-3 and phophorylated isoforms of IGFBP-1 with FGF-2 as a mediator.
Keywords: Diabetes mellitus, Birth weight, Retinopathy, IGF-I, IGF-II, IGFBP-1, IGFBP-3, FGF-2
Current Diabetes Reviews
Title: The Clinical Significance of IGF-I in Maternal Serum During Pregnancy in Type 1 Diabetes
Volume: 3 Issue: 3
Author(s): Finn Friis Lauszus
Affiliation:
Keywords: Diabetes mellitus, Birth weight, Retinopathy, IGF-I, IGF-II, IGFBP-1, IGFBP-3, FGF-2
Abstract: Insulin-like growth factors (IGFs) constitute a system of peptides that promote mitosis, growth, and organ development by both paracrine and endocrine pathways, their bioavailability being modulated by at least six specific IGF-binding proteins (IGFBP). In type 1diabetic pregnancies IGF-I and -II in maternal serum are associated with birth weight and their action modulated by IGFBP-3 and phosporylated isoforms of IGFBP-1. Pregnancy-associated plasma protein-A (PAPP-A), a proteolytic substance of IGFBPs, is probably a modulator in early diabetic pregnancy while human placental growth hormone (hPGH) regulates the effect of IGF-I in pregnancy of diabetic and non-diabetic pregnancies. IGF-I in maternal serum increases concomitantly with progression of diabetic retinopathy despite good glycemic control in pregnancy. The role of the new insulin analogues in improving this effect has yet to be established. Retinopathy in pregnancy is associated with an elevated level of fibroblast growth factor-2 (FGF-2) and highly-phosphorylated IGFBP-1, the latter further increasing the level of free IGF-I and FGF-2. Thus, the effect on development of retinopathy may be directly mediated by IGF-I or indirectly by a modifying effect of IGFBP-3 and phophorylated isoforms of IGFBP-1 with FGF-2 as a mediator.
Export Options
About this article
Cite this article as:
Finn Friis Lauszus , The Clinical Significance of IGF-I in Maternal Serum During Pregnancy in Type 1 Diabetes, Current Diabetes Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339907781368922
DOI https://dx.doi.org/10.2174/157339907781368922 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry Vascular Disease and Risk Factors in Chronic Kidney Disease
Vascular Disease Prevention (Discontinued) Secondary Prevention of Ischemic Stroke
Current Drug Targets <i>In silico</i> Molecular Docking and ADME Studies of 1,3,4-Thiadiazole Derivatives in Relation to <i>in vitro</i> PON1 Activity
Current Computer-Aided Drug Design Prooxidant-Antioxidant Balance and Antioxidant Properties of Thuja orientalis L: A Potential Therapeutic Approach for Diabetes Mellitus
Current Molecular Pharmacology Nanoparticles Functionalized with Venom-Derived Peptides and Toxins for Pharmaceutical Applications
Current Pharmaceutical Biotechnology Emerging Potential of Citrus Flavanones as an Antioxidant in Diabetes and its Complications
Current Topics in Medicinal Chemistry Linagliptin: A Novel Methylxanthin Based Approved Dipeptidyl Peptidase-4 Inhibitor
Current Drug Targets Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Preface:
Current Topics in Medicinal Chemistry Analyzing the Amperometric Response of a Glucose Oxidase Sensor Applying Mathematical Models
Current Analytical Chemistry Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets A Review on Molecular Mechanisms and Patents of Marine-derived Anti-thrombotic Agents
Current Drug Targets Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design Small Artery Remodeling in Obesity and Insulin Resistance
Current Vascular Pharmacology Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential
Current Neuropharmacology The Role of Combined Assessment of Defense Against Oxidative Stress and Inflammation in the Evaluation of Peripheral Arterial Disease
Current Molecular Medicine Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis
Current Clinical Pharmacology